Adeena Musheer

Dr. Adeena Musheer

Dow University of Health Sciences (DUHS) Karachi Pakistan
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KFKaneez Fatima
Kaneez Fatima
TATalal Almas
Talal Almas
SLShan Lakhani
Shan Lakhani
AJArshia Jahangir
Arshia Jahangir
AAAbdullah Ahmed
Abdullah Ahmed
AMAdeena Musheer
Adeena Musheer
COVID-19 has proved to be a serious, and consequential disease that has affected millions of people globally. Previously, the adverse effects of proton pump inhibitors (PPI) have been observed with increasing the risk of pneumonia and COVID-19. This meta-analysis aims to address the relationship between the use of PPI and the severity of COVID-19 infection. We conducted a systemic literature search from PUBMED, Science Direct, and Cinahl from December 2019 to January 2022. Published and unpublished randomized control trials and cohort studies were included. Review Manager was used for all statistical analyses. In total, 14 studies were included in this systemic review and meta-analysis. Outcomes of interest include: (1) susceptibility of COVID-19 infection and (2) severity of COVID-19 (defined as the composite of poor outcomes: ICU admission, need for oxygen therapy, need for a ventilator, or death), and (3) mortality due to COVID-19. PPI use was marginally associated with a nominal but statistically significant increase in the risk of COVID-19 infection (OR 1.05 [1.01, 1.09]; I2 97%, p = 0.007). PPI use also increased the risk of the composite poor outcome (OR 1.84 [1.71, 1.99]; I2 98%, p < 0.00001) and mortality (OR 1.12 [1.00, 1.25]; I2 84%, p = 0.05) in patients with COVID-19.

30 July 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
NANouman Aziz
Nouman Aziz
WNWaseem Nabi
Waseem Nabi
HUHafiz Muhammad Umer
Hafiz Muhammad Umer
FKFaiza Khan
Faiza Khan
HHHira Habib
Hira Habib
MSMoazzam Shahzad
Moazzam Shahzad


21 July 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAdeena Musheer
Adeena Musheer
MMMuhammad S. Mannan
Muhammad S. Mannan
MKMuhammad W. Khan
Muhammad W. Khan
ABAribah Bhatti
Aribah Bhatti
TBTuba Basit
Tuba Basit
SMSafwan Muhammad
Safwan Muhammad
Objectives: Cervical cancer is the fourth leading cause of cancer mortality in women worldwide. PD-L1 is expressed in 34.4% to 96% of cervical cancers. Camrelizumab is an anti-PD-1 IgG4 antibody with antitumor activity. This study evaluates the efficacy and safety of camrelizumab in cervical cancer. Methods: A systematic search of PubMed, Embase, Web of Science, Cochrane Library, Ovid MEDLINE, and Scopus was performed to identify studies of pathologically confirmed cervical cancer treated with camrelizumab alone or in combination with chemotherapy or VEGFR-TKIs, including apatinib or famitinib. Eligible studies included randomized trials, single-arm trials, cohort studies, and case-control studies. Pooled proportions with 95% CIs were calculated using R version 4.4.1. Heterogeneity was assessed using I 2 , and evidence certainty was evaluated using GRADE. Results: Eight studies comprising 382 patients were included. Camrelizumab was evaluated as monotherapy, with chemotherapy, or with VEGFR-TKIs. The pooled objective response rate (ORR) was 0.62 (95% CI: 0.32-0.85). The disease control rate (DCR), assessed in 7 studies including 297 patients, was 0.83 (95% CI: 0.60-0.94). The pooled partial response (PR) rate was 0.45 (95% CI: 0.29-0.62), while the complete response (CR) rate was 0.15 (95% CI: 0.10-0.23). Progressive disease (PD) outcomes were reported in a cohort of 297 patients, corresponding to a proportion of 0.16 (95% CI: 0.06-0.36), and stable disease (SD) demonstrated a pooled proportion of 0.30 (95% CI: 0.19-0.44). Commonly reported adverse events included neutropenia, anemia, leukopenia, hypertension, lymphopenia, and myelosuppression. Conclusions: Camrelizumab demonstrates clinically meaningful antitumor activity in cervical cancer, particularly in combination regimens, though toxicity requires careful monitoring.

2 October 2026 in International Journal of Cancer Care and Delivery
Verified
Journal Article
Open access
PDF file
YLYan Leyfman
Yan Leyfman
AMAdeena Musheer
Adeena Musheer
ZBZara Baloch
Zara Baloch
DPDiksha Sanjana Pasnoor
Diksha Sanjana Pasnoor
NLNoam Levi
Noam Levi
ARTURO LOAIZA-BONILLAARTURO LOAIZA-BONILLA
ARTURO LOAIZA-BONILLA
From the 2026 National Summit on Hematologic Cancers

10 August 2026 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAdeena Musheer
Adeena Musheer
MMMuhammad S. Mannan
Muhammad S. Mannan
MKMuhammad W. Khan
Muhammad W. Khan
AJAyesha Junaid
Ayesha Junaid
TBTuba Basit
Tuba Basit
MSMoazzam Shahzad
Moazzam Shahzad
Objectives: Durvalumab consolidation following concurrent chemoradiotherapy (CRT) has become the standard of care for patients with unresectable stage III non–small cell lung cancer (NSCLC). However, survival outcomes reported in clinical trials and real-world studies have been inconsistent, making it difficult to understand the efficacy and safety of this treatment modality fully. Our study aims to pool the available evidence to evaluate the impact of durvalumab in patients with unresectable stage III NSCLC. Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for studies including randomized controlled trials and real-world observational studies that assess durvalumab after definitive CRT in unresectable stage III NSCLC, till January 2026. Data extracted included median overall survival (OS), median progression-free survival (PFS), and survival rates. Random-effects meta-analyses were performed to pool OS and PFS. Results: A total of 3 studies comprising 861 patients with unresectable stage III NSCLC were included. Durvalumab consolidation after definitive CRT showed no statistically significant effect on OS (HR: 1.06, 95% CI: 0.52-2.14; I ²=51.6%; P =0.1268) or PFS (HR: 0.87, 95% CI: 0.45-1.68; I ²=49.6%; P =0.1374). Heterogeneity was moderate for both outcomes. In addition to these primary outcomes, multiple secondary efficacy and safety outcomes were systematically evaluated, including overall response rate and treatment-related adverse effects. Conclusions: Durvalumab consolidation demonstrates a favorable safety profile, but outcomes remain variable across studies. These findings highlight the importance of biomarker-driven patient selection and prospective real-world evaluation to maximize the clinical benefit of durvalumab in unresectable stage III NSCLC.